95
Pharmacokinetics

Pharmacokinetics

Embed Size (px)

Citation preview

Page 1: Pharmacokinetics

Pharmacokinetics

Page 2: Pharmacokinetics

Drug Effectiveness• Dose-response (DR) curve:

Depicts the relation between drug dose and magnitude of drug effect

• Drugs can have more than one effect

• Drugs vary in effectiveness– Different sites of action– Different affinities for receptors

• The effectiveness of a drug is considered relative to its safety (therapeutic index)

Page 3: Pharmacokinetics

Dose-Effect Curves

Page 4: Pharmacokinetics
Page 5: Pharmacokinetics

Therapeutic Index

This is a figure of two different dose response curves. You can obtain a different dose response curve for any system that the drug effects. When you vary the drug, this is the Independent variable, what you are measuring is the % of individuals responding to the drug. Here we see the drugs effects on hypnosis and death. Notice that the effective dose for 50 % of the people is 100 mg and if you double the dose to 200 mg then 1 % of your subjects die. Thus, if you want to use this drug to hypnotize 99 % of your subjects, in the process you will kill 2-3 % of your subjects.

This is a figure of two different dose response curves. You can obtain a different dose response curve for any system that the drug effects. When you vary the drug, this is the Independent variable, what you are measuring is the % of individuals responding to the drug. Here we see the drugs effects on hypnosis and death. Notice that the effective dose for 50 % of the people is 100 mg and if you double the dose to 200 mg then 1 % of your subjects die. Thus, if you want to use this drug to hypnotize 99 % of your subjects, in the process you will kill 2-3 % of your subjects.

Page 6: Pharmacokinetics

Drug Safety and Effectiveness• Not all people respond to a similar dose of a drug

in the exact same manner, this variability is based upon individual differences and is associated with toxicity. This variability is thought to be caused by: – Pharmacokinetic factors contribute to differing

concentrations of the drug at the target area. – Pharmacodynamic factors contribute to differing

physiological responses to the same drug concentration. – Unusual, idiosyncratic, genetically determined or

allergic, immunologically sensitized responses.

Page 7: Pharmacokinetics

Pharmacokinetics• Drug molecules interact with target sites to effect the

nervous system– The drug must be absorbed into the bloodstream and then

carried to the target site(s)

• Pharmacokinetics is the study of drug absorption, distribution within body, and drug elimination over time.– Absorption depends on the route of administration– Drug distribution depends on how soluble the drug

molecule is in fat (to pass through membranes) and on the extent to which the drug binds to blood proteins (albumin)

– Drug elimination is accomplished by excretion into urine and/or by inactivation by enzymes in the liver

Page 8: Pharmacokinetics

Overview

Page 9: Pharmacokinetics

Study of d[drug] over time

Page 10: Pharmacokinetics

Pharmacokinetics

Page 11: Pharmacokinetics

DISPOSITION OF DRUGS

The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill, 1996).

Page 12: Pharmacokinetics

Routes of Administration

• Routes of Administration:Orally: • Rectally: • Inhalation: Absorption through mucous

membranes: • Topical: • Parenterally:

– Intravenous: – Intramuscular: – Subcutaneous:

Page 13: Pharmacokinetics

Routes of Administration

Page 14: Pharmacokinetics

Drug Delivery Systems

• Tablets • Injections (Syringe) • Cigarettes • Beverages • Patches • Suppositories

• Candy • Gum • Implants • Gas • Creams• Others?

– Stamps

– Bandana

Page 15: Pharmacokinetics

Membranes• Types of Membranes:• Cell Membranes: This barrier is permeable to many drug

molecules but not to others, depending on their lipid solubility. Small pores, 8 angstroms, permit small molecules such as alcohol and water to pass through.

• Walls of Capillaries: Pores between the cells are larger than most drug molecules, allowing them to pass freely, without lipid solubility being a factor.

• Blood/Brain Barrier: This barrier provides a protective environment for the brain. Speed of transport across this barrier is limited by the lipid solubility of the psychoactive molecule.

• Placental Barrier: This barrier separates two distinct human beings but is very permeable to lipid soluble drugs.

Page 16: Pharmacokinetics

Drug Distribution

• Dependent upon its route of administration and target area, every drug has to be absorbed, by diffusion, through a variety of bodily tissue.

• Tissue is composed of cells which are encompassed within membranes, consisting of 3 layers, 2 layers of water-soluble complex lipid molecules (phospholipid) and a layer of liquid lipid, sandwiched within these layers. Suspended within the layers are large proteins, with some, such as receptors, transversing all 3 layers.

• The permeability of a cell membrane, for a specific drug, depends on a ratio of its water to lipid solubility. Within the body, drugs may exist as a mixture of two interchangeable forms, either water (ionized-charged) or lipid (non-ionized) soluble. The concentration of two forms depends on characteristics of the drug molecule (pKa, pH at which 50% of the drug is ionized) and the pH of fluid in which it is dissolved.

• In water soluble form, drugs cannot pass through lipid membranes, but to reach their target area, they must permeate a variety of types of membranes.

Page 17: Pharmacokinetics

Pharmacokinetics vs Pharmacodynamics…concept• Fluoxetine increases plasma

concentrations of amitriptyline. This is a pharmacokinetic drug interaction.

• Fluoxetine inhibits the metabolism of amitriptyline and increases the plasma concentration of amitriptytline.

Page 18: Pharmacokinetics

Pharmacokinetics vs Pharmacodynamics…concept• If fluoxetine is given with tramadol serotonin

syndrom can result. This is a pharmacodynamic drug interaction.

• Fluoxetine and tramadol both increase availability of serotonin leading to the possibility of “serotonin overload” This happens without a change in the concentration of either drug.

Page 19: Pharmacokinetics

Basic Parameters

• In the next few slides the basic concepts and paramaters will be described and explained.

• In pharmacokinetics the body is represented as a single or multiple compartments in to which the drug is distributed.

• Some of the parameters are therefore a little abstract as we know the body is much more complicated !

Page 20: Pharmacokinetics

V

Volume 100 L

Clearance10 L/hr

Volume of Distribution, Clearance and Elimination Rate Constant

Page 21: Pharmacokinetics

V

Volume 100 L (Vi)

Clearance10 L/hr

Volume of Distribution, Clearance and Elimination Rate Constant

V2

Cardiac and Skeletal Muscle

Page 22: Pharmacokinetics

VVolume 100 L (Vi)

Clearance10 L/hr

V2

Cardiac and Skeletal Muscle

Volume of Distribution =

Dose_______Plasma Concentration

Page 23: Pharmacokinetics

VVolume 100 L (Vi)

Clearance10 L/hr

V2

Cardiac and Skeletal Muscle

Clearance =Volume of blood cleared of drug per unit time

Page 24: Pharmacokinetics

VVolume 100 L (Vi)

Clearance10 L/hr

V2

Cardiac and Skeletal Muscle

Clearance = 10 L/hrVolume of Distribution = 100 LWhat is the Elimination Rate Constant (k) ?

Page 25: Pharmacokinetics

CL = kVk = 10 Lhr -1 = 0.1 hr -1

100 L

10 % of the “Volume” is cleared (of drug) per hour k = Fraction of drug in the body removed per hour

Page 26: Pharmacokinetics

CL = kVIf V increases then k must decrease as CL is constant

Page 27: Pharmacokinetics

Important Concepts

• VD is a theoretical Volume and determines the loading dose.

• Clearance is a constant and determines the maintenance dose.

• CL = kVD.

• CL and VD are independent variables.

• k is a dependent variable.

Page 28: Pharmacokinetics

Volume of Distribution (Vd)

Apparent volume of distribution is the theoretical volume that would have to be available for drug to disperse in if the concentration everywhere in the body were the same as that in the plasma or serum, the place where drug concentration sampling generally occurs.

Page 29: Pharmacokinetics

Volume of Distribution

• An abstract concept

• Gives information on HOW the drug is distributed in the body

• Used to calculate a loading dose

Page 30: Pharmacokinetics

Loading Dose

Dose = Cp(Target) x VdDose = Cp(Target) x Vd

Page 31: Pharmacokinetics

Question

• What is the loading dose required for drug A if;

• Target concentration is 10 mg/L

• Vd is 0.75 L/kg

• Patients weight is 75 kg

• Answer is on the next slide

Page 32: Pharmacokinetics

Answer: Loading Dose of Drug A

• Dose = Target Concentration x VD

• Vd = 0.75 L/kg x 75 kg = 56.25 L

• Target Conc. = 10 mg/L• Dose = 10 mg/L x 56.25 L• = 565 mg• This would probably be rounded to 560 or

even 500 mg.

Page 33: Pharmacokinetics

Clearance (CL)

• Ability of organs of elimination (e.g. kidney, liver) to “clear” drug from the bloodstream.

• Volume of fluid which is completely cleared of drug per unit time.

• Units are in L/hr or L/hr/kg• Pharmacokinetic term used in determination

of maintenance doses.

Page 34: Pharmacokinetics

Clearance

• Volume of blood in a defined region of the body that is cleared of a drug in a unit time.

• Clearance is a more useful concept in reality than t 1/2 or kel since it takes into account blood flow rate.

• Clearance varies with body weight.

• Also varies with degree of protein binding.

Page 35: Pharmacokinetics

Clearance

• Rate of elimination = kel D,– Remembering that C = D/Vd

– And therefore D= C Vd

– Rate of elimination = kel C Vd

• Rate of elimination for whole body = CLT CCombining the two,

CLT C = kel C Vd and simplifying gives:

CLT = kel Vd

Page 36: Pharmacokinetics

Maintenance DoseCalculation

• Maintenance Dose = CL x CpSSav

• CpSSav is the target average steady state drug concentration

• The units of CL are in L/hr or L/hr/kg

• Maintenance dose will be in mg/hr so for total daily dose will need multiplying by 24

Page 37: Pharmacokinetics

Question

• What maintenance dose is required for drug A if;

• Target average SS concentration is 10 mg/L

• CL of drug A is 0.015 L/kg/hr• Patient weighs 75 kg

• Answer on next slide.

Page 38: Pharmacokinetics

Answer

• Maintenance Dose = CL x CpSSav

• CL = 0.015 L/hr/kg x 75 = 1.125 L/hr

• Dose = 1.125 L/hr x 10 mg/L = 11.25 mg/hr

• So will need 11.25 x 24 mg per day= 270 mg

Page 39: Pharmacokinetics

Half-Life and k

• Half-life is the time taken for the drug concentration to fall to half its original value

• The elimination rate constant (k) is the fraction of drug in the body which is removed per unit time.

Page 40: Pharmacokinetics

Drug Half-Life

Page 41: Pharmacokinetics

Half-Life

• C = Co e - kt

• C/Co = 0.50 for half of the original amount

• 0.50 = e – k t

• ln 0.50 = -k t ½

• -0.693 = -k t ½

• t 1/2 = 0.693 / k

Page 42: Pharmacokinetics

Drug Elimination

ΔC

Δt= KC

dC

dt= −KC

Ct = C0e−Kt

Page 43: Pharmacokinetics

Use of t ½ and kel data

• If drug has short duration of action, design drug with larger t ½ and smaller kel

• If drug too toxic, design drug with

smaller t ½ and larger kel

Page 44: Pharmacokinetics

Drug Concentration

Time

C1

Exponential decay

dC/dt C= -k.C

C2

Page 45: Pharmacokinetics

Log Concn.

Time

C0

C0/2 t1/2

t1/2

t1/2

Time to eliminate ~ 4 t1/2

Page 46: Pharmacokinetics

Integrating:

Cp2 = Cp1.e-kt

Logarithmic transform:lnC2= lnC1 - kt

logC2 = logC1 - kt/2.303

Elimination Half-Life: t1/2 = ln2/k

t1/2 = 0.693/k

Page 47: Pharmacokinetics

Steady-State

• Steady-state occurs after a drug has been given for approximately five elimination half-lives.

• At steady-state the rate of drug administration equals the rate of elimination and plasma concentration - time curves found after each dose should be approximately superimposable.

Page 48: Pharmacokinetics

100100

187.5187.5194194

175175

150150

757587.587.5 9494 9797

5050

200200

100100……

……

Accumulation to Steady State

100 mg given every half-life

Page 49: Pharmacokinetics

C

t

Cpav

Four half lives to reach steady state

Page 50: Pharmacokinetics

What is Steady State (SS) ?Why is it important ?

• Rate in = Rate Out

• Reached in 4 – 5 half-lives (linear kinetics)

• Important when interpreting drug concentrations in time-dependent manner or assessing clinical response

Page 51: Pharmacokinetics

Therapeutic Drug Monitoring

Some Principles

Page 52: Pharmacokinetics

Therapeutic Index

• Therapeutic index = toxic dose/effective dose

• This is a measure of a drug’s safety– A large number = a wide margin of safety– A small number = a small margin of safety

Page 53: Pharmacokinetics

Drug Concentrations may beUseful when there is:

• An established relationship between concentration and response or toxicity

• A sensitive and specific assay

• An assay that is relatively easy to perform

• A narrow therapeutic range

• A need to enhance response/preventtoxicity

Page 54: Pharmacokinetics

Why Measure DrugConcentrations?

• Lack of therapeutic response

• Toxic effects evident

• Potential for non-compliance

• Variability in relationship of dose andconcentration

• Therapeutic/toxic actions not easilyquantified by clinical endpoints

Page 55: Pharmacokinetics

Potential for Error when using TDM• Assuming patient is at steady-state• Assuming patient is actually taking the drug

as prescribed• Assuming patient is receiving drug as prescribed• Not knowing when the [drug] was measured in

relation to dose administration • Assuming the patient is static and that changes in

condition don’t affect clearance• Not considering drug interactions

Page 56: Pharmacokinetics

Acute vs Steady State

Page 57: Pharmacokinetics

Elimination by the Kidney• Excretion - major

1) glomerular filtrationglomerular structure, size constraints,

protein binding

2) tubular reabsorption/secretion- acidification/alkalinization,- active transport, competitive/saturable, organic acids/bases

- protein binding

• Metabolism - minor

Page 58: Pharmacokinetics

Elimination by the Liver• Metabolism - major

1) Phase I and II reactions

2) Function: change a lipid soluble to more water soluble molecule to excrete in kidney

3) Possibility of active metabolites with same or different properties as parent molecule

• Biliary Secretion – active transport, 4 categories

Page 59: Pharmacokinetics

The Enterohepatic Shunt

Portal circulation

Liver

gall bladder

Gut

Bile

duct

Drug

Biotransformation;glucuronide produced

Bile formation

Hydrolysis bybeta glucuronidase

Page 60: Pharmacokinetics

Liver P450 systems• Liver enzymes inactivate some drug molecules

– First pass effect (induces enzyme activity)

• P450 activity is genetically determined:– Some persons lack such activity leads to higher drug

plasma levels (adverse actions)

– Some persons have high levels leads to lower plasma levels (and reduced drug action)

• Other drugs can interact with the P450 systems– Either induce activity (apparent tolerance)

– Inactivate an enzyme system

Page 61: Pharmacokinetics

Drug Metabolism and pK

Page 62: Pharmacokinetics

How are [drug] measured?

• Invasive: blood, spinal fluid, biopsy

• Noninvasive: urine, feces, breath, saliva

• Most analytical methods designed for plasma analysis

• C-14, H-3

Page 63: Pharmacokinetics
Page 64: Pharmacokinetics

Therapeutic Window

• Useful range of concentration over which a drug is therapeutically beneficial. Therapeutic window may vary from patient to patient

• Drugs with narrow therapeutic windows require smaller and more frequent doses or a different method of administration

• Drugs with slow elimination rates may rapidly accumulate to toxic levels….can choose to give one large initial dose, following only with small doses

Page 65: Pharmacokinetics

Shape different for IV injection

Page 66: Pharmacokinetics

Distribution

• Rate & Extent depend upon– Chemical structure of drug– Rate of blood flow– Ease of transport through membrane– Binding of drug to proteins in blood– Elimination processes

Page 67: Pharmacokinetics

• Partition Coefficients: ratio of solubility of a drug in water or in an aqueous buffer to its solubility in a lipophilic, non-polar solvent

• pH and ionization: Ion Trapping

Page 68: Pharmacokinetics

The Compartment Model

• We can generally think of the body as a series of interconnected well-stirred compartments within which the [drug] remains fairly constant. BUT movement BETWEEN compartments important in determining when and for how long a drug will be present in body.

Page 69: Pharmacokinetics

Partitioning into body fat and other tissues

        A large, nonpolar compartment. Fat has low blood supply—less than 2% of cardiac output, so drugs are delivered to fat relatively slowly•For practical purposes: partition into body fat important following acute dosing only for a few highly lipid-soluble drugs and environmental contaminants which are poorly metabolized and remain in body for long period of time

Page 70: Pharmacokinetics

IMPORTANT EFFECTS OF pH PARTITIONING:

        urinary acidification will accelerate the excretion of weak bases and retard that of weak acids; alkalination has the opposite effects

        increasing plasma pH (by addition of NaHCO3) will cause weakly acidic drugs to be

extracted from the CNS into the plasma; reducing plasma pH (by administering a carbonic anhydrase inhibitor) will cause weakly acidic drugs to be concentrated in the CNS, increasing their toxicity

Page 71: Pharmacokinetics

Renal Elimination

• Glomerular filtration: molecules below 20 kDa pass into filtrate. Drug must be free, not protein bound.

• Tubular secretion/reabsorption: Active transport. Followed by passive and active. DP=D + P. As D transported, shift in equilibrium to release more free D. Drugs with high lipid solubility are reabsorbed passively and therefore slowly excreted. Idea of ion trapping can be used to increase excretion rate---traps drug in filtrate.

Page 72: Pharmacokinetics

Plasma Proteins that Bind Drugs

• albumin: binds many acidic drugs and a few basic drugs

-globulin and an 1acid glycoprotein

have also been found to bind certain basic drugs

Page 73: Pharmacokinetics

A bound drug has no effect!

• Amount bound depends on:• 1)     free drug concentration• 2)     the protein concentration • 3) affinity for binding sites

% bound: __[bound drug]__________ x 100

[bound drug] + [free drug]

Page 74: Pharmacokinetics

% Bound

• Renal failure, inflammation, fasting, malnutrition can have effect on plasma protein binding.

• Competition from other drugs can also affect % bound.

Page 75: Pharmacokinetics

An Example

• Warfarin (anticoagulant) protein bound ~98%• Therefore, for a 5 mg dose, only 0.1 mg of drug is

free in the body to work!• If patient takes normal dose of aspirin at same

time (normally occupies 50% of binding sites), the aspirin displaces warfarin so that 96% of the warfarin dose is protein-bound; thus, 0.2 mg warfarin free; thus, doubles the injested dose

Page 76: Pharmacokinetics

Volume of Distribution

• C = D/VVd is the apparent volume of distributionC= [drug] in plasma at some timeD= total [drug] in system

Vd gives one as estimate of how well the drug is distributed. Vd < 0.071 L/kg indicate the drug is mainly in the circulatory system.

Vd > 0.071 L/kg indicate the drug has entered specific tissues.

Page 77: Pharmacokinetics

Conc. vs. time plots

C = Co - kt ln C = ln Co - kt

Page 78: Pharmacokinetics

Types of Kinetics Commonly Seen

Zero Order Kinetics

• Rate = k

• C = Co - kt

• Constant rate of elimination regardless of [D]plasma

• C vs. t graph is LINEAR

First Order Kinetics• Rate = k C• C = Co e-kt

• Rate of elimination proportional to plasma concentration. Constant fraction of drug eliminated per unit time.

• C vs. t graph is NOT linear, decaying exponential. Log C vs. t graph is linear.

Page 79: Pharmacokinetics

Example of Zero Order Elimination: Pharmacokinetics of Ethanol

• Ethanol is distributed in total body water.• Mild intoxication at 1 mg/ml in plasma.• How much should be ingested to reach it?

Answer: 42 g or 56 ml of pure ethanol (VdxC)Or 120 ml of a strong alcoholic drink like whiskey

• Ethanol has a constant elimination rate = 10 ml/h• To maintain mild intoxication, at what rate must

ethanol be taken now? at 10 ml/h of pure ethanol, or 20 ml/h of drink.

Page 80: Pharmacokinetics

First-Order Kinetics

Page 81: Pharmacokinetics

To reiterate: Comparison

• First Order Elimination– [drug] decreases

exponentially w/ time

– Rate of elimination is proportional to [drug]

– Plot of log [drug] or ln[drug] vs. time are linear

– t 1/2 is constant regardless of [drug]

• Zero Order Elimination– [drug] decreases linearly

with time

– Rate of elimination is constant

– Rate of elimination is independent of [drug]

– No true t 1/2

Page 82: Pharmacokinetics

Route of Administration Determines Bioavailability (AUC)

Page 83: Pharmacokinetics

AUC: An Indicator of Bioavailability

• Dose is proportional to [drug] in tissues.

• [drug], in turn, is proportional to the Area Under the Curve in a Concentration-decay curve.

• Thus, we have k = dose/AUC

• Because oral administration is full of barriers, the fraction, F, that is available by entering the general circulation, may not be significant.

• Thus, FD = k(AUC)

or k = FD/AUC

Page 84: Pharmacokinetics

• Combining these 2 equations gives us:

FDpo/AUCpo = Div/AUCiv

• And thus, F = AUCpoDiv

AUCivDpo

• More generally, the relative bioavailability, F = AUCADoseB

AUCBDoseA

Page 85: Pharmacokinetics

AUC: IV Administration

Page 86: Pharmacokinetics

AUC

• For IV bolus, the AUC represents the total amount of drug that reaches the circulatory system in a given time.

• Dose = CLT AUC

Page 87: Pharmacokinetics

AUC: Oral Administration

Page 88: Pharmacokinetics

Bioavailability

• The fraction of the dose of a drug (F) that enters the general circulatory system,

F= amt. of drug that enters systemic circul.

Dose administered

F = AUC/Dose

Page 89: Pharmacokinetics

Bioavailability

• A concept for oral administration• Useful to compare two different drugs or different

dosage forms of same drug

• Rate of absorption depends, in part, on rate of dissolution (which in turn is dependent on chemical structure, pH, partition coefficient, surface area of absorbing region, etc.) Also first-pass metabolism is a determining factor

Page 90: Pharmacokinetics

The Effect of the Liver First Pass

• F = 1-E, where E is fraction of the dose elim via the liver.

• Cltot = D/AUC

• Clhep = Cltot-Clren

• Clhep = E × LBF, which is liver blood flow or E = Clhep/LBF

• Combining the 1st eq with the last gives

F = 1-E = 1-Clhep

LBF

Page 91: Pharmacokinetics

Rowland’s Equation

• F = 1-E = 1-Clhep

LBF

This very useful equation calculates the magnitude of the effect of the liver’s 1st pass of an oral dose and, more precisely, to predict it from and i.v. test.

Thus, if E < 0.10, then, clearly, bioavailability F > 0.90.

Page 92: Pharmacokinetics

P450 Interactions

• Substrate: Is the drug metabolized via a specific hepatic isoenzyme?

• Inhibitor: does a specific drug inhibit a specific hepatic isoenzyme?– Would expect this to interfere with drug inactivation

• Inducer: does a specific drug enhance a specific hepatic isoenzyme?– Would expect this to speed up drug inactivation

Page 93: Pharmacokinetics

Drug-CYP InteractionsEnzyme (CYP) Substrate Inhibitor Inducer

1A2 Clozapine, haloperidol Cimetidine Tobacco smoke

2B6 Bupropion Thiotepa Phenobarbital

2C19 Citalopram Fluoxetine Prednisone

2C9 Fluoxetine Paroxetine Secobarbital

2D6 Most ADs, APs CPZ, ranitidine Dexamethasone

2E1 Gas anesthetics Disulfiram Ethanol

3A4,5,7 Alprazolam Grapefruit juice Glucocorticoid

–http://www.georgetown.edu/departments/pharmacology/clinlist.html

Page 94: Pharmacokinetics

Drug Enantioners• A drug molecule may be organized in such a way that

the same atoms are mirror images– Enantioners represent drug molecules that are structurally

different (spatial configutation)• Different physical properties

– Light rotation (levo = left; dextro = right)– Melting points

• Different biological activities (typically: dextro > levo)

– Fenfluramine = racemic mix of• dextro-fenfluramine• levo-fenfluramine

• Enantiomers often have different affinity for receptors

Page 95: Pharmacokinetics